DrugBiological
Dinutuximab clinical trials
Also written Ch14.18, Unituxin and Qarziba.
Keep track of what changes. Save the dinutuximab studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Development codes
- Ch14.18
- 15
Studies by the year they started
34 studies that test it; most in 2022 (4)
| Year | Studies |
|---|---|
| 2001 | 2 |
| 2002 | 1 |
| 2005 | 1 |
| 2009 | 1 |
| 2010 | 1 |
| 2012 | 1 |
| 2013 | 3 |
| 2014 | 1 |
| 2015 | 1 |
| 2016 | 1 |
| 2017 | 1 |
| 2019 | 3 |
| 2020 | 2 |
| 2021 | 2 |
| 2022 | 4 |
| 2023 | 1 |
| 2024 | 3 |
| 2025 | 2 |
| 2026 | 3 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 4 · Other 30
National Cancer Institute (NCI) (8) · New Approaches to Neuroblastoma Therapy Consortium (3) · University of Birmingham (2) · United Therapeutics (2) · St. Anna Kinderkrebsforschung (2) · Children's Hospital Los Angeles (1) · Nationwide Children's Hospital (1) · Children's Oncology Group (1)
Often tested with
Tested in the same studies.
Irinotecan (9) · Temozolomide (6) · Sargramostim (6) · Aldesleukin (5) · Isotretinoin (4) · Granulocyte-Macrophage Colony-Stimulating Factor (4) · Natural Killer Cell (3) · Lenalidomide (2)
Studies
Open first, then newest update. How each study uses dinutuximab is read from its arms, and is right about nine times in ten.
Testing it · 34
- Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk NeuroblastomaRecruitingPhase 3National Cancer Institute (NCI)NCT06172296Written as Dinutuximab
- Dinutuximab-beta and Chemotherapy in Newly Diagnosed High-Risk NeuroblastomaRecruitingPhase 1Chang Gung Memorial HospitalNCT07688252Written as Dinutuximab Beta
- Phase I/II Trial of Dinutuximab Beta in Combination With Irinotecan and Rapamycin in Pediatric, Adolescents and Adult Patients With Relapsed/Refractory Bone Tumors.Not yet recruitingPhase 1/2University Hospital, Strasbourg, FranceNCT07853105Written as Dinutuximab beta, Sirolimus and Irinotecan
- NANT 2021-02: Randomized MIBG With Vorinostat/Dinutuximab/Vorinostat + DinutuximabNot yet recruitingPhase 2New Approaches to Neuroblastoma Therapy ConsortiumNCT07261241Written as Dinutuximab
- NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) TrialRecruitingPhase 2New Approaches to Neuroblastoma Therapy ConsortiumNCT06450041Written as Dinutuximab
- Chemoimmunotherapy Combined With Autologous NK Cell Therapy for Pediatric Patients With Refractory and Relapsed High-Risk Neuroblastoma and GanglioneuroblastomaRecruitingPhase 3Federal Research Institute of Pediatric Hematology, Oncology and ImmunologyNCT07375563Written as irinotecan, temozolomide, dinutuximab beta, NK-cell product
- A Multi-Arm, Platform Trial For Relapsed NeuroblastomaRecruitingPhase 1/2University of BirminghamNCT07334301Written as Dinutuximab beta
- Quadruple Immunotherapy for NeuroblastomaRecruitingPhase 2Hong Kong Children's HospitalNCT05754684Written as Dinutuximab beta
- High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)RecruitingPhase 3Gustave Roussy, Cancer Campus, Grand ParisNCT04221035Written as Dinutuximab Beta
- International Phase I Trial of Dinutuximab Beta With VDC/IE in GD2-Positive Ewing SarkomaNot yet recruitingPhase 1Prof. Dr. Dirk ReinhardtNCT06839703Written as Dinutuximab beta
- Chemo-immunotherapy in Patients Under 18 Years of Age With Bone and Soft Tissue SarcomasRecruitingPhase 3N.N. Petrov National Medical Research Center of OncologyNCT06669013Written as dinutuximab beta
- High Risk Neuroblastoma Study 1.8 of SIOP-Europe (SIOPEN)RecruitingPhase 3St. Anna KinderkrebsforschungNCT01704716Written as ch14.18/CHO
- Rapid Administration Pilot for Infusing DinutuximabActive, not recruitingPhase 2Children's Hospital Los AngelesNCT05421897Written as Dinutuximab with Chemotherapy
- NK Cells Infusions With Irinotecan, Temozolomide, and DinutuximabActive, not recruitingPhase 1/2Nationwide Children's HospitalNCT04211675Written as Dinutuximab
- Lenalidomide and Dinutuximab With or Without Isotretinoin in Treating Younger Patients With Refractory or Recurrent NeuroblastomaActive, not recruitingPhase 1National Cancer Institute (NCI)NCT01711554Written as Dinutuximab
- Monoclonal Antibody Ch14.18, Sargramostim, Aldesleukin, and Isotretinoin After Autologous Stem Cell Transplant in Treating Patients With NeuroblastomaCompletedPhase 3National Cancer Institute (NCI)NCT01041638Written as Dinutuximab
- Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk NeuroblastomaCompletedPhase 2National Cancer Institute (NCI)NCT03786783Written as Dinutuximab
- Activity Study of Bevacizumab With Temozolomide ± Irinotecan for Neuroblastoma in ChildrenCompletedPhase 2University of BirminghamNCT02308527Written as Dinutuximab Beta
- Immunotherapy of Relapsed Refractory Neuroblastoma With Expanded NK CellsActive, not recruitingPhase 1New Approaches to Neuroblastoma Therapy ConsortiumNCT02573896Written as Dinutuximab
- Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With NeuroblastomaCompletedPhase 3National Cancer Institute (NCI)NCT00026312Written as Dinutuximab
See all 34 studies that test dinutuximab →
Given in every arm · 9 — dinutuximab is usual care beside what is tested
- Testing the Addition of Iberdomide to Therapy in People With Neuroblastoma That Has Come Back, Not Responded to Treatment, or Gotten WorseRecruitingPhase 1/2National Cancer Institute (NCI)NCT07437963Written as Dinutuximab
- Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)RecruitingPhase 3Children's Oncology GroupNCT03126916Written as Dinutuximab
- Study Combining Dinutuximab Beta With Two Chemotherapy Regimens in NeuroblastomaRecruitingPhase 1Princess Maxima Center for Pediatric OncologyNCT06485947Written as Dinutuximab beta
- Testing the Combination of Two Immunotherapy Drugs (Magrolimab and Dinutuximab) in Patients With Relapsed or Refractory Neuroblastoma or Relapsed OsteosarcomaTerminatedPhase 1National Cancer Institute (NCI)NCT04751383Written as Dinutuximab
- Phase I Study of 131-I mIBG Followed by Nivolumab & Dinutuximab Beta Antibodies in Children With Relapsed/Refractory NeuroblastomaActive, not recruitingPhase 1University Hospital Southampton NHS Foundation TrustNCT02914405Written as Ch14.18/CHO
- Irinotecan Hydrochloride, Temozolomide, and Dinutuximab With or Without Eflornithine in Treating Patients With Relapsed or Refractory NeuroblastomaActive, not recruitingPhase 2Children's Oncology GroupNCT03794349Written as Dinutuximab
- MIBG With Dinutuximab +/- VorinostatCompletedPhase 1New Approaches to Neuroblastoma Therapy ConsortiumNCT03332667Written as Dinutuximab
- NB2013-HR German (GPOH) / Dutch (DCOG) TrialTerminatedPhase 2University of CologneNCT02641782Written as antibody ch14.18
- Long Term Continuous Infusion ch14.18/CHO Plus s.c. Aldesleukin (IL-2)Status unknownPhase 1/2St. Anna KinderkrebsforschungNCT01701479Written as ch14.18/CHO
Codes
What other systems call dinutuximab · ClinicalTrials.gg INT004079
- MeSH (NLM) C112746dinutuximabConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 7SQY4ZUD30DINUTUXIMABConfirmed FDA, NLM, Wikidata
- RxNorm 1606274Confirmed FDA, Wikidata
- Wikidata Q21011236dinutuximabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C1570DinutuximabOne source FDA
- DrugBank DB09077One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C112746 | dinutuximab | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 7SQY4ZUD30 | DINUTUXIMAB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1606274 | — | Confirmed FDA, Wikidata |
| Wikidata | Q21011236 | dinutuximab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C1570 | Dinutuximab | One source FDA |
| DrugBank | DB09077 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.